Artificial intelligence in drug repurposing for rare diseases: a mini-review

Lucas Cortial,Vincent Montero,Sébastien Tourlet,Joanie Del Bano,Olivier Blin
DOI: https://doi.org/10.3389/fmed.2024.1404338
IF: 3.9
2024-05-22
Frontiers in Medicine
Abstract:Drug repurposing, the process of identifying new uses for existing drugs beyond their original indications, offers significant advantages in terms of reduced development time and costs, particularly in addressing unmet medical needs in rare diseases. Artificial intelligence (AI) has emerged as a transformative force in healthcare, and by leveraging AI technologies, researchers aim to overcome some of the challenges associated with rare diseases. This review presents concrete case studies, as well as pre-existing platforms, initiatives, and companies that demonstrate the application of AI for drug repurposing in rare diseases. Despite representing a modest part of the literature compared to other diseases such as COVID-19 or cancer, the growing interest, and investment in AI for drug repurposing in rare diseases underscore its potential to accelerate treatment availability for patients with unmet medical needs.
medicine, general & internal
What problem does this paper attempt to address?